Traws Pharma (STU:0T2) FCF Margin % : -7,964.71% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Traws Pharma's Free Cash Flow for the three months ended in Dec. 2023 was €-4.06 Mil. Traws Pharma's Revenue for the three months ended in Dec. 2023 was €0.05 Mil. Therefore, Traws Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was -7,964.71%.

As of today, Traws Pharma's current FCF Yield % is -111.44%.

The historical rank and industry rank for Traws Pharma's FCF Margin % or its related term are showing as below:

STU:0T2' s FCF Margin % Range Over the Past 10 Years
Min: -9995.67 Med: -5118.21 Max: -272.68
Current: -7959.81

During the past 13 years, the highest FCF Margin % of Traws Pharma was -272.68%. The lowest was -9995.67%. And the median was -5118.21%.

STU:0T2's FCF Margin % is ranked worse than
90.73% of 1036 companies
in the Biotechnology industry
Industry Median: -147.71 vs STU:0T2: -7959.81

Traws Pharma FCF Margin % Historical Data

The historical data trend for Traws Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma FCF Margin % Chart

Traws Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-956.64

-9,989.47

-8,623.00

-7,221.60

-7,950.24

Traws Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-6,916.98	-8,159.62	-7,818.87	-7,900.00	-7,964.71

Competitive Comparison of Traws Pharma's FCF Margin %

For the Biotechnology subindustry, Traws Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Traws Pharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Traws Pharma's FCF Margin % falls into.

Traws Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Traws Pharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-16.457	/	0.207
	=	-7,950.24 %

Traws Pharma's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-4.062	/	0.051
	=	-7,964.71 %

Traws Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Traws Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Traws Pharma (STU:0T2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (STU:0T2) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ONTX:USA 0T2:Germany

Address

12 Penns Trail, Newtown, PA, USA, 18940

Website

https://www.onconova.com

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (STU:0T2) Headlines

No Headlines